본문으로 건너뛰기
← 뒤로

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

Future oncology (London, England) 2026 Vol.22(9) p. 1015-1029

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Homet Moreno B, Beaumont JL, Purnajo I, McManus S, Powles T

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Gupta S, Loriot Y, et al. (2026). How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.. Future oncology (London, England), 22(9), 1015-1029. https://doi.org/10.1080/14796694.2026.2645984
MLA Gupta S, et al.. "How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.." Future oncology (London, England), vol. 22, no. 9, 2026, pp. 1015-1029.
PMID 41925239

같은 제1저자의 인용 많은 논문 (5)